153 related articles for article (PubMed ID: 12701984)
1. Initial findings of the AASK: African Americans with hypertensive kidney disease benefit from an ACE inhibitor.
Rahman M
Cleve Clin J Med; 2003 Apr; 70(4):304-5, 309-10, 312. PubMed ID: 12701984
[TBL] [Abstract][Full Text] [Related]
2. ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial.
Douglas JG; Agodoa L
Kidney Int Suppl; 2003 Feb; (83):S74-6. PubMed ID: 12864879
[TBL] [Abstract][Full Text] [Related]
3. Design and baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study.
Wright JT; Kusek JW; Toto RD; Lee JY; Agodoa LY; Kirk KA; Randall OS; Glassock R
Control Clin Trials; 1996 Aug; 17(4 Suppl):3S-16S. PubMed ID: 8889350
[TBL] [Abstract][Full Text] [Related]
4. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
Agodoa LY; Appel L; Bakris GL; Beck G; Bourgoignie J; Briggs JP; Charleston J; Cheek D; Cleveland W; Douglas JG; Douglas M; Dowie D; Faulkner M; Gabriel A; Gassman J; Greene T; Hall Y; Hebert L; Hiremath L; Jamerson K; Johnson CJ; Kopple J; Kusek J; Lash J; Lea J; Lewis JB; Lipkowitz M; Massry S; Middleton J; Miller ER; Norris K; O'Connor D; Ojo A; Phillips RA; Pogue V; Rahman M; Randall OS; Rostand S; Schulman G; Smith W; Thornley-Brown D; Tisher CC; Toto RD; Wright JT; Xu S;
JAMA; 2001 Jun; 285(21):2719-28. PubMed ID: 11386927
[TBL] [Abstract][Full Text] [Related]
5. Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.
Thornley-Brown D; Wang X; Wright JT; Randall OS; Miller ER; Lash JP; Gassman J; Contreras G; Appel LJ; Agodoa LY; Cheek D
Arch Intern Med; 2006 Apr; 166(7):797-805. PubMed ID: 16606818
[TBL] [Abstract][Full Text] [Related]
6. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Wright JT; Bakris G; Greene T; Agodoa LY; Appel LJ; Charleston J; Cheek D; Douglas-Baltimore JG; Gassman J; Glassock R; Hebert L; Jamerson K; Lewis J; Phillips RA; Toto RD; Middleton JP; Rostand SG;
JAMA; 2002 Nov; 288(19):2421-31. PubMed ID: 12435255
[TBL] [Abstract][Full Text] [Related]
7. The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?
Sica DA
J Clin Hypertens (Greenwich); 2003; 5(2):159-67. PubMed ID: 12671332
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for the management of special populations: racial and ethnic populations.
Ferdinand KC
Am J Hypertens; 2003 Nov; 16(11 Pt 2):50S-54S. PubMed ID: 14625162
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.
Norris K; Bourgoigne J; Gassman J; Hebert L; Middleton J; Phillips RA; Randall O; Rostand S; Sherer S; Toto RD; Wright JT; Wang X; Greene T; Appel LJ; Lewis J;
Am J Kidney Dis; 2006 Nov; 48(5):739-51. PubMed ID: 17059993
[TBL] [Abstract][Full Text] [Related]
10. Hypertensive African Americans with kidney disease should seek advice from doctor about blood pressure medication.
Ethn Dis; 2001; 11(1):3-4. PubMed ID: 11289247
[No Abstract] [Full Text] [Related]
11. Rationale for angiotensin II receptor blockers in patients with low-renin hypertension.
Jamerson KA
Am J Kidney Dis; 2000 Sep; 36(3 Suppl 1):S24-30. PubMed ID: 10986156
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial.
Bhatnagar V; O'Connor DT; Schork NJ; Salem RM; Nievergelt CM; Rana BK; Smith DW; Bakris GL; Middleton JP; Norris KC; Wright JT; Cheek D; Hiremath L; Contreras G; Appel LJ; Lipkowitz MS
J Hypertens; 2007 Oct; 25(10):2082-92. PubMed ID: 17885551
[TBL] [Abstract][Full Text] [Related]
13. Effect of blood pressure control and antihypertensive drug regimen on quality of life: the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study.
Kusek JW; Lee JY; Smith DE; Milligan S; Faulkner M; Cornell CE; Kopple JD; Greene PG
Control Clin Trials; 1996 Aug; 17(4 Suppl):40S-46S. PubMed ID: 8889353
[TBL] [Abstract][Full Text] [Related]
14. Lessons from the African-American Study of Kidney Disease and Hypertension: an update.
Toto RD
Curr Hypertens Rep; 2006 Oct; 8(5):409-12. PubMed ID: 16965728
[TBL] [Abstract][Full Text] [Related]
15. The African American Study of Kidney Disease and Hypertension (AASK): new findings.
Sica DA; Douglas JG
J Clin Hypertens (Greenwich); 2001; 3(4):244-51. PubMed ID: 11498655
[TBL] [Abstract][Full Text] [Related]
16. The rationale and design of the AASK cohort study.
Appel LJ; Middleton J; Miller ER; Lipkowitz M; Norris K; Agodoa LY; Bakris G; Douglas JG; Charleston J; Gassman J; Greene T; Jamerson K; Kusek JW; Lewis JA; Phillips RA; Rostand SG; Wright JT
J Am Soc Nephrol; 2003 Jul; 14(7 Suppl 2):S166-72. PubMed ID: 12819323
[TBL] [Abstract][Full Text] [Related]
17. American Heart Association 2001 scientific sessions: late-breaking science-ACE inhibitor therapy in African-Americans.
Fox R
Circulation; 2001 Nov; 104(21):E9052. PubMed ID: 11727732
[No Abstract] [Full Text] [Related]
18. Clinical trials report. The effect of Ramipril versus Amlodipine on renal outcomes in hypertension nephrosclerosis.
Vidt DG
Curr Hypertens Rep; 2001 Oct; 3(5):379-80. PubMed ID: 11551370
[No Abstract] [Full Text] [Related]
19. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
20. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
Trials; 2015 Dec; 16():581. PubMed ID: 26686682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
